) for 7 days. Systolic BP, elevated in Ang II-infused rats (176Ϯ5 mm Hg) versus controls (109Ϯ2 mm Hg, PϽ0.01), was reduced by pioglitazone (134Ϯ2 mm Hg) or rosiglitazone (123Ϯ2 mm Hg). In mesenteric small arteries studied in a pressurized myograph, media/lumen ratio was increased (PϽ0.05) and acetylcholine-induced relaxation impaired in Ang II-infused rats (PϽ0.05); both were normalized by the thiazolidinediones. In Ang II-infused rats, vascular DNA synthesis (by 3 H-thymidine incorporation); expression of cell cycle proteins cyclin D1 and cdk4, angiotensin II type 1 receptors, vascular cell adhesion molecule-1, and platelet and endothelial cell adhesion molecule; and nuclear factor-B activity were increased. These changes were abrogated by pioglitazone or rosiglitazone. Conclusions-Thiazolidinedione PPAR-␥ activators attenuated the development of hypertension, corrected structural abnormalities, normalized cell growth, and improved endothelial dysfunction induced by Ang II and prevented upregulation of angiotensin II type 1 receptors, cell cycle proteins, and proinflammatory mediators. Thiazolidinediones may be useful in the prevention and/or treatment of hypertension, particularly when it is associated with insulin resistance or diabetes mellitus. Key Words: hypertension Ⅲ arteries Ⅲ remodeling Ⅲ muscle, smooth Ⅲ inflammation I nsulin resistance has emerged as a mechanism linking diabetes mellitus and hypertension. 1 Thiazolidinediones (TZDs) such as pioglitazone and rosiglitazone are highaffinity ligands for peroxisome proliferator-activated receptor (PPAR)-␥, a transcription factor of the nuclear hormone receptor superfamily, 2 and are used as insulin-sensitizing drugs in type II diabetes mellitus. TZDs increase transcription of certain insulin-sensitive genes by binding to nuclear PPAR-␥, which together with the retinoid X receptor binds to specific DNA sequences, the peroxisome proliferator response elements. 3 Expression of PPAR-␥, initially thought to be restricted to adipose tissue, is now known to occur in endothelium, 4 vascular smooth muscle cells (VSMCs), 5 and monocytes/macrophages. 6 Angiotensin (Ang) II plays a major role in hypertension. Ang II-induced hypertensive rats exhibit abnormal vascular structure. 7 VSMC growth, apoptosis, cell migration, inflammation, and increased deposition of extracellular matrix proteins such as collagen and fibronectin, as well as changes in anchoring of cells to the fibrillar components of the extracellular matrix, are some of the processes that contribute to vascular remodeling induced by Ang II. 8 TZDs have blood pressure (BP)-lowering effects, 9,10 but mechanisms for this are unclear. PPAR-␥ agonists may directly modulate vascular structure and function independently of their role on lipid metabolism. Here, we tested the hypothesis that PPAR-␥ activators such as pioglitazone or rosiglitazone have effects on Ang II type 1 (AT 1 ) receptors and that Ang II-induced increases in DNA synthesis, cell cycle proteins, nuclear factor-B (NF-B), vascular cell adhesion molecule-1 (VCAM-1), and platelet and endothelial cell adhesion molecule (PECAM) are abrogated by these agents in Ang II-infused rats.
Methods

Animal Experiments
The study was approved by the Animal ) in drinking water to evaluate effects of BP lowering. Systolic BP was measured by the tail-cuff method. Rats were not fasted overnight, and they were killed by decapitation. The mesenteric bed was dissected; one segment was used for preparation of small arteries, and the rest was cleaned of fat, frozen in liquid nitrogen, and kept at Ϫ80°C for Western blot assay and for DNA extraction. A portion of aorta was fixed in 10% buffered formalin solution and embedded in paraffin. Tissue sections (7 m thick) were prepared for immunohistochemical analysis. Fat and endothelium were removed from another portion of aorta that was then frozen in liquid nitrogen and kept at Ϫ80°C for measurement of NF-B activity.
Preparation and Study of Small Arteries
Third-order superior mesenteric arteries (length Ϸ2 mm) were placed in cold physiological salt solution containing (in mmol/L) NaCl 120, NaHCO 3 
Evaluation of Collagen Deposition in Aorta
Paraffin-embedded sections of aorta were stained with Sirius Red. Collagen in the media was quantified microscopically with the Northern Eclipse imaging program.
Evaluation of DNA Synthesis
DNA synthesis in mesenteric arteries was evaluated by radiolabeled 3 H-thymidine incorporation. 12 Rats received intraperitoneal injections of [methyl-
3 H] thymidine (0.5 mCi/kg, ICN Biomedicals Inc) 24 hours before they were killed. DNA was extracted with phenol/ chloroform and its concentration determined spectrophotometrically. DNA specific activity (cpm/100 g of DNA) reflecting the incorporation of 3 H-thymidine into smooth muscle DNA over the last 24 hours in vivo was measured by scintillation counting.
Western Blot Analysis of Cyclin D1, cdk4, VCAM-1, PECAM, PPAR-␥, and AT 1 and AT 2 Receptors
Protein was extracted from frozen tissue, 12 and concentration was determined with the Micro BCA protein assay kit (Pierce). Aliquots were separated by electrophoresis on a 10% to 15% polyacrylamide gel at 100 V for 1 hour and transferred onto a polyvinylidene difluoride membrane in a cooling system at 100 V for 1 hour. Membranes were incubated with specific antibody to cyclin D1, cdk4, VCAM-1, PECAM, PPAR-␥, and AT 1 and AT 2 receptors (Santa Cruz Biotechnology Inc). Signals were revealed with chemiluminescence and visualized autoradiographically. Optical density of bands was quantified by scanning and with ImageQuant (Molecular Dynamics). The density of the bands from each blot was normalized to that of controls (taken as 100%). MeanϮSEM values were calculated from 4 blots.
Electrophoretic Mobility Shift Assay for NF-B
Frozen aorta was homogenized; suspended in solution containing 50 mmol/L Tris (pH 7.4), 1 mmol/L sodium orthovanadate, 1 g/mL pepstatin, 1 g/mL aprotinin, and 1 g/mL leupeptin; and centrifuged (4000g, 4 minutes, 4°C). 13 The resuspended pellet was lysed for 30 minutes in 20 mmol/L HEPES, pH 7.9, containing 350 mmol/L NaCl, 20% glycerol, 1 mmol/L MgCl 2 , 0.5 mmol/L EDTA, 0.1 mmol/L EGTA, 1% NP-40, 1 mmol/L PMSF, 1 mmol/L sodium orthovanadate, 1 g/mL pepstatin, 1 g/mL aprotinin, and 1 g/mL leupeptin and centrifuged (13 000g, 10 minutes, 4°C). The supernatant was stored at Ϫ80°C. Protein concentration was quantified by BioRad reagent. Twenty micrograms of nuclear protein was incubated at room temperature for 30 minutes in binding reaction medium (50 mmol/L Tris-HCl, 250 mmol/L NaCl, 20% glycerol, 2.5 mmol/L EDTA, 2.5 mmol/L DTT, 5 mmol/L MgCl 2 , and 0.25 mg/mL poly dI-dC) with 0.5 ng of 32 P-dATP end-labeled doublestranded oligonucleotide containing the NF-B binding site (Promega, 5Ј-AGTTGAGGGGACTTTCCCAGGC-3Ј, based on the rat sequence) from the major histocompatibility complex enhancer. HeLa cell nuclear extracts and water were respectively positive and negative controls. NF-B (p65-x) antibody from Santa Cruz was used for supershift. In competition assays, 50 ng of unlabeled oligonucleotides was used. The DNA-protein complexes were analyzed on 4% polyacrylamide gel in 0.5X Tris-borate-EDTA buffer. The gel was then dried and exposed to 32 P-sensitive screen. Optical density in the region of NF-B (p65) was quantified for each lane with the PhosphoImager system. MeanϮSEM values were calculated from 3 electrophoretic mobility shift assays.
Measurement of Plasma Renin Activity, Aldosterone, and Lipids
Plasma renin activity was measured by radioimmunoassay of Ang I produced after a 2-hour incubation of plasma at 37°C and pH 6.5. 14 
Data Analysis
Values are presented as meanϮSEM. Results were compared by 1-way ANOVA, followed by Tukey-Kramer test. PϽ0.05 was considered significant.
Results
Body Weight, BP, Plasma Renin Activity, Aldosterone, and Lipids
After 7-day treatment, body weight was similar in all groups ( Table 1 ). The BP increase induced by Ang II infusion (PϽ0.01 versus control) was abolished by pioglitazone and rosiglitazone (Table 1 ) and, in parallel experiments, by hydralazine (124Ϯ1 mm Hg; Figure 1A ). Rosiglitazone slightly increased BP in normal rats.
As expected, plasma renin activity was significantly depressed in Ang II-infused rats and was unaffected by pioglitazone or rosiglitazone ( Table 1 ). The plasma aldosterone/ renin activity ratio rose 100-fold with Ang II and was unaffected by pioglitazone or rosiglitazone. Ang II, pioglitazone, and rosiglitazone had no effect on plasma cholesterol, triacylglycerol, or nonesterified fatty acids.
Collagen Deposition in Aorta
Ang II, pioglitazone, and rosiglitazone did not affect vascular collagen deposition after the 7-day Ang II infusion ( Table 2) .
Morphology and Endothelial Function of Resistance Arteries
Ang II infusion resulted in an increase (PϽ0.05) in media/ lumen ratio of resistance arteries (Table 2) , which was normalized by treatment with pioglitazone or rosiglitazone ( Table 2) . Hydralazine did not affect vascular structural changes induced by Ang II ( Figure 1B) . Media crosssectional area of resistance arteries was similar in all groups.
Ang II-infused rats exhibited impaired acetylcholineinduced relaxation ( Figures 1C and 2A) , which improved (PϽ0.05) under pioglitazone and rosiglitazone (Figure 2A ) but not hydralazine ( Figure 1C ). Endothelium-independent relaxation by SNP was similar in all groups ( Figure 1B ). Relaxation to acetylcholine and SNP was unaffected by the TZDs alone (data not shown).
Resistance Artery DNA Synthesis and Expression of Cell Cycle Proteins
Vascular DNA synthesis ( 3 H-thymidine incorporation) increased 1.8-fold in Ang II-infused rats ( Figure 3A ) and decreased with pioglitazone and rosiglitazone. Expression of cyclin D1 and cdk4 increased 3-and 4-fold, respectively, in Ang II-infused rats ( Figure  3B ). This effect was abrogated by the TZDs (Figure 3B ).
Vascular Expression of Angiotensin Receptors
Expression of AT 1 and AT 2 receptors in resistance arteries of Ang II-infused rats increased 2-fold (Figure 4) . Pioglitazone-and rosiglitazone-treated Ang II-infused rats had normal levels of AT 1 Figure 1 . A, Systolic BP in Ang II-infused rats treated without or with hydralazine (Hydr) for 7 days. Results are meanϮSEM (nϭ5 to 8 per group). *PϽ0.05 vs control, †PϽ0.05 vs Ang II group. B, Media/lumen ratio (as %) in small mesenteric arteries of Ang II-infused rats treated without or with hydralazine for 7 days. Results are meanϮSEM (nϭ5 to 8 per group). *PϽ0.05 vs control. C, Endothelium-dependent relaxation in response to acetylcholine (ACH) in small mesenteric arteries of Ang II-infused rats treated without or with hydralazine for 7 days. 
Vascular Expression of NF-B and Adhesion Molecules
NF-B, which regulates expression of inflammatory mediators, was activated 3-fold in blood vessels of Ang II-infused rats ( Figures 5A  and 1D ), and VCAM-1 and PECAM expression increased significantly ( Figures 5B and 5C and Figure 1E ). These effects were abolished by pioglitazone and rosiglitazone ( Figures 5B and 5C ) but not by hydralazine ( Figures 1D and 1E ). The TZDs alone had no effect on NF-B, VCAM-1, or PECAM.
Vascular Expression of PPAR-␥
PPAR-␥ expression in mesenteric arteries was unaffected by Ang II but was enhanced by pioglitazone or rosiglitazone ( Figure 6 ).
Discussion
In this study, pioglitazone and rosiglitazone prevented hypertension in Ang II-infused rats and abrogated the structural, functional, and molecular changes in blood vessels. We show the novel finding that the PPAR-␥ activators had direct effects on the vascular wall, with downregulation of AT 1 receptors and upregulation of AT 2 receptors that led to inhibition of cell growth and inflammation.
TZDs have antihypertensive effects in other hypertensive models. 9, 10 The novel finding that these agents reduced resistance artery remodeling may be explained by a direct action of TZDs on the vessel wall. BP lowering does not appear to play a role, because hydralazine decreased BP without any effect on vascular structure, endothelial function, or inflammatory mediators. These in vivo data confirm and extend results from in vitro studies in which PPAR-␥ ligands were shown to downregulate AT 1 receptor expression [15] [16] [17] and inhibit Ang II-stimulated DNA synthesis in VSMCs 18 by modulation of cyclin-dependent kinase inhibitors. 19 Pioglitazone and rosiglitazone also decreased cell growth in small arteries. We recently found that rosiglitazone induced VSMC apoptosis, which could contribute to this effect (unpublished data). Although molecular mechanisms remain to be clarified, inhibition of growth and acceleration of apoptotic rate by PPAR-␥ via increased expression of AT 2 receptors may decrease the cell proliferation induced by Ang II via AT 1 receptors. Ang II also induces vascular remodeling via collagen deposition. 8, 20 The absence of changes in collagen found during the short 7-day Ang II infusion in the present study may contribute to the absence of net vascular growth observed in the Ang II-infused groups. Indeed, small artery structural changes after Ang II infusion were the so-called eutrophic remodeling (unchanged media cross-sectional area). 21 A role of AT 1 receptors in the Ang II effects reported here is supported by previous data that demonstrated that ACE inhibition or antagonism of AT 1 receptors prevented or reversed hypertensive changes in resistance artery structure. 22 Rosiglitazone used alone slightly increased BP. TZDs may have direct vascular effects mediated via activation of PPAR-␥ and systemic effects on BP that could be in part PPAR-␥ independent and unrelated to the renin-angiotensin-aldosterone system. 23 TZDs are insulin-sensitizing agents and may exert water-and salt-retaining effects, 24, 25 and they could have other renal actions 26 that contribute to BP elevation. In our previous study, 27 PPAR-␥ expression increased with age during development of hypertension, whereas it did not change in the present study in Ang II-infused rats despite the BP rise. Thus, expression of vascular PPAR-␥ may have effects on vascular remodeling in hypertension that are independent of BP levels. Pioglitazone and rosiglitazone protect against impairment of endothelial function associated with insulin resistance. 9, 10 Mechanisms whereby TZDs improved endothelial dysfunction of resistance arteries of Ang II-infused rats could include attenuation of Ang II-induced oxidative stress 28, 29 secondary to downregulation of AT 1 receptors, resulting in less nitric oxide degradation. We recently observed that pioglitazone and rosiglitazone decreased oxidative stress in blood vessels of Ang II-infused rats (unpublished data). An effect on agonist-mediated calcium uptake into VSMCs, 10 which would tilt the balance of constriction and relaxation in favor of the latter, could also play a role. Decreased BP could also contribute to improvement of endothelial dysfunction, but hydralazine, which lowered BP, had no effect in the present experiments, which suggests that BP lowering did not participate importantly in these findings.
Expression of PPAR-␥ was thought to be limited primarily to adipose tissue and regulation of lipid metabolism. However, in the present study, neither of the TZDs had any effect on plasma cholesterol, triacylglycerol, or free fatty acid concentrations. Inflammation is an important mechanism in the progression of atherosclerosis. PPAR-␥ activators blunt macrophage activation, as demonstrated by inhibition of gelatinase B (MMP-9), inducible nitric oxide synthase activity, and tumor necrosis factor-␣ release. 6, 30 Activation of PPAR-␥ in human endothelial cells can inhibit cell proliferation, modulate plasminogen activator inhibitor-1 expression, reduce endothelin-1 production, and induce apoptosis. 31 Endothelial cell PPAR-␥ activation may inhibit activator protein-1 and NF-B pathways that regulate expression of adhesion molecules. PPAR-␥ activators may protect the vasculature by inhibiting the migration of monocytes into the vessel wall through inhibition of upregulation of adhesion molecules. 32 In the present study, both PPAR-␥ agonists abrogated upregulation of transcription factor NF-B and adhesion molecules, in agreement with previous reports. 6, 33 Our results have important implications for the clinical use of PPAR-␥ ligands. In addition to playing a role in adipocyte differentiation, we demonstrate that TZDs have direct effects on the vascular wall. These vascular effects could be PPAR-␥ mediated or PPAR-␥ independent. 34 Together with evidence that dominant negative mutations in human PPAR-␥ are associated not only with severe insulin resistance and diabetes mellitus but also with hypertension, 35 this suggests that use of TZDs to activate PPAR-␥ may represent an approach to protect the vasculature in hypertension. TZDs may be promising therapeutic agents not only to control metabolic abnormalities in diabetes but also for prevention and/or treatment of hypertension, particularly when associated with insulin resistance or diabetes mellitus. 
